#3947 net monitor verification
#3947 net monitor trial

The occurrence of slow or no reperfusion/microvascular obstruction (MVO) was associated with a lower ejection fraction, increased ventricular volumes and infarct size, and a greater risk of major adverse cardiac events (MACE), which severely affected the prognosis of patients who have had an MI. The incidence of slow or no reperfusion was 5–60%, depending on the study population, evaluation method, and time. However, a significant proportion of patients still face low or no reperfusion at the myocardial tissue level, even though the infarcted blood vessels have been recanalized. Prompt induction of complete and sustained infarct-related artery recanalization is paramount, and primary percutaneous coronary intervention (PCI) is currently the treatment of choice. According to the data of the China Cardiovascular Disease Report 2017 Summary, the mortality of acute myocardial infarction (AMI) in China is on the rise. It is well known that myocardial infarction (MI) is associated with high mortality rates.

#3947 net monitor trial

Trial registrationĬhinese Clinical Trial Registry, ChiCTR1900021440. This trial will evaluate the efficacy and safety of Danhong Injection, as well as its optimal timing of intervention to prevent MVO in patients with STEMI. Psychological status and dietary patterns will be evaluated using Hamilton Depression Rating Scale and Food Frequency Questionnaire as the relevant indicators. The safety outcomes include bleeding events, adverse events, and abnormal changes in routine blood tests. Health quality will be assessed with the 12-item Short Form Health Survey.

The major adverse cardiovascular events and hospital readmission events will be recorded. The secondary outcomes are the degree of STR, Thrombolysis in Myocardial Infarction (TIMI) flow grade, TIMI myocardial perfusion grade, left ventricular ejection fraction, N-terminal prohormone brain natriuretic peptide, high-sensitivity C-reactive protein, and infarct size expressed as area under the curve for cardiac troponin I (cTnI) and for creatine kinase MB. The primary outcome is rate of ST-segment resolution (STR) ≥ 70% at 90 min after PCI. A total of 336 patients with STEMI receiving percutaneous coronary intervention (PCI) will be randomly assigned to conventional treatment, the preoperative Danhong Injection, or the postoperative Danhong Injection. The DIRECTION study is a multicenter, prospective, randomized, evaluator-blind study.

#3947 net monitor verification

However, evidence of a rigorously designed verification study is still lacking, and the intervention timing of Danhong Injection is uncertain.

Several studies have described the effects of Danhong Injection.

Issue of shares pursuant to the Company’s dividend reinvestment scheme.No treatment has convincingly been proven to be beneficial for microvascular obstruction (MVO) in patients with ST-elevation myocardial infarction (STEMI). Details of the person discharging managerial responsibilities/person closely associatedĭetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitorĭetails of the transaction(s): section to be repeated for (i) each type of instrument (ii) each type of transaction (iii) each date and (iv) each place where transactions have been conductedĭescription of the financial instrument, type of instrument